The Institute for Clinical and Economic Review presents an approach to evaluating the price of new drugs for hepatitis C based on budget parameters used by payers in a draft report released Nov. 17.
Based on the approach, it estimates a new combination drug for hepatitis C that cost $34,000 to $42,000 would be...